BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 37805657)

  • 1. URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers.
    Ding Z; Pan Y; Shang T; Jiang T; Lin Y; Yang C; Pang S; Cui X; Wang Y; Feng XF; Xu M; Pei M; Chen Y; Li X; Ding J; Tan Y; Wang H; Dong L; Wang L
    Nat Commun; 2023 Oct; 14(1):6269. PubMed ID: 37805657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galectin-1-mediated MET/AXL signaling enhances sorafenib resistance in hepatocellular carcinoma by escaping ferroptosis.
    Hsu TW; Su YH; Chen HA; Liao PH; Shen SC; Tsai KY; Wang TH; Chen A; Huang CY; Shibu MA; Wang WY; Shen SC
    Aging (Albany NY); 2023 Jul; 15(13):6503-6525. PubMed ID: 37433225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ZNF498 promotes hepatocellular carcinogenesis by suppressing p53-mediated apoptosis and ferroptosis via the attenuation of p53 Ser46 phosphorylation.
    Zhang X; Zheng Q; Yue X; Yuan Z; Ling J; Yuan Y; Liang Y; Sun A; Liu Y; Li H; Xu K; He F; Wang J; Wu J; Zhao C; Tian C
    J Exp Clin Cancer Res; 2022 Feb; 41(1):79. PubMed ID: 35227287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation.
    Ma MKF; Lau EYT; Leung DHW; Lo J; Ho NPY; Cheng LKW; Ma S; Lin CH; Copland JA; Ding J; Lo RCL; Ng IOL; Lee TKW
    J Hepatol; 2017 Nov; 67(5):979-990. PubMed ID: 28647567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma.
    Tang J; Sui CJ; Wang DF; Lu XY; Luo GJ; Zhao Q; Lian QY; Jeong S; Lin XM; Zhu YJ; Zheng B; Wu R; Wang Q; Liu XL; Liu JF; Xia Q; Wu G; Gu J; Wang HY; Chen L
    Theranostics; 2020; 10(12):5384-5397. PubMed ID: 32373219
    [No Abstract]   [Full Text] [Related]  

  • 6. SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase.
    Xu FL; Wu XH; Chen C; Wang K; Huang LY; Xia J; Liu Y; Shan XF; Tang N
    Cell Death Dis; 2023 Jan; 14(1):22. PubMed ID: 36635256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis.
    Li Y; Yang W; Zheng Y; Dai W; Ji J; Wu L; Cheng Z; Zhang J; Li J; Xu X; Wu J; Yang M; Feng J; Guo C
    J Exp Clin Cancer Res; 2023 Jan; 42(1):6. PubMed ID: 36604718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein phosphatase 2A-B55β mediated mitochondrial p-GPX4 dephosphorylation promoted sorafenib-induced ferroptosis in hepatocellular carcinoma via regulating p53 retrograde signaling.
    Qian B; Che L; Du ZB; Guo NJ; Wu XM; Yang L; Zheng ZX; Gao YL; Wang MZ; Chen XX; Xu L; Zhou ZJ; Lin YC; Lin ZN
    Theranostics; 2023; 13(12):4288-4302. PubMed ID: 37554285
    [No Abstract]   [Full Text] [Related]  

  • 9. Donafenib and GSK-J4 Synergistically Induce Ferroptosis in Liver Cancer by Upregulating HMOX1 Expression.
    Zheng C; Zhang B; Li Y; Liu K; Wei W; Liang S; Guo H; Ma K; Liu Y; Wang J; Liu L
    Adv Sci (Weinh); 2023 Aug; 10(22):e2206798. PubMed ID: 37330650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53.
    Wang W; Cheng JW; Qin JJ; Hu B; Li X; Nijampatnam B; Velu SE; Fan J; Yang XR; Zhang R
    Cancer Lett; 2019 Sep; 459():156-167. PubMed ID: 31181320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-30e-3p Influences Tumor Phenotype through
    Gramantieri L; Pollutri D; Gagliardi M; Giovannini C; Quarta S; Ferracin M; Casadei-Gardini A; Callegari E; De Carolis S; Marinelli S; Benevento F; Vasuri F; Ravaioli M; Cescon M; Piscaglia F; Negrini M; Bolondi L; Fornari F
    Cancer Res; 2020 Apr; 80(8):1720-1734. PubMed ID: 32015093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
    Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
    J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 inhibits tumor cell invasion via the degradation of snail protein in hepatocellular carcinoma.
    Lim SO; Kim H; Jung G
    FEBS Lett; 2010 Jun; 584(11):2231-6. PubMed ID: 20385133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated p53 with Histone Deacetylase Inhibitor Enhances L-Fucose-Mediated Drug Delivery through Induction of Fucosyltransferase 8 Expression in Hepatocellular Carcinoma Cells.
    Okagawa Y; Takada K; Arihara Y; Kikuchi S; Osuga T; Nakamura H; Kamihara Y; Hayasaka N; Usami M; Murase K; Miyanishi K; Kobune M; Kato J
    PLoS One; 2016; 11(12):e0168355. PubMed ID: 27977808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib triggers ferroptosis via inhibition of HBXIP/SCD axis in hepatocellular carcinoma.
    Zhang L; Li XM; Shi XH; Ye K; Fu XL; Wang X; Guo SM; Ma JQ; Xu FF; Sun HM; Li QQ; Zhang WY; Ye LH
    Acta Pharmacol Sin; 2023 Mar; 44(3):622-634. PubMed ID: 36109580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HCAR1/MCT1 Regulates Tumor Ferroptosis through the Lactate-Mediated AMPK-SCD1 Activity and Its Therapeutic Implications.
    Zhao Y; Li M; Yao X; Fei Y; Lin Z; Li Z; Cai K; Zhao Y; Luo Z
    Cell Rep; 2020 Dec; 33(10):108487. PubMed ID: 33296645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de-palmitoylation.
    Shi Z; Li Z; Jin B; Ye W; Wang L; Zhang S; Zheng J; Lin Z; Chen B; Liu F; Zhang B; Ding X; Yang Z; Shan Y; Yu Z; Wang Y; Chen J; Chen Q; Roberts LR; Chen G
    Clin Transl Med; 2023 Jun; 13(6):e1300. PubMed ID: 37337470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macropinocytosis is an alternative pathway of cysteine acquisition and mitigates sorafenib-induced ferroptosis in hepatocellular carcinoma.
    Byun JK; Lee S; Kang GW; Lee YR; Park SY; Song IS; Yun JW; Lee J; Choi YK; Park KG
    J Exp Clin Cancer Res; 2022 Mar; 41(1):98. PubMed ID: 35287706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Akt inhibitor augments anti-proliferative efficacy of a dual mTORC1/2 inhibitor by FOXO3a activation in p53 mutated hepatocarcinoma cells.
    Patra T; Meyer K; Ray RB; Kanda T; Ray R
    Cell Death Dis; 2021 Nov; 12(11):1073. PubMed ID: 34759291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma.
    Chen Y; Li L; Lan J; Cui Y; Rao X; Zhao J; Xing T; Ju G; Song G; Lou J; Liang J
    Mol Cancer; 2022 Jan; 21(1):11. PubMed ID: 34983546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.